Novavax (NASDAQ: NVAX) has reported that the European Medicines Agency has recommended granting a conditional marketing authorization for Novavax’ COVID-19 vaccine to prevent COVID-19 in people from 18 years of age and older. If authorized, NVX-CoV2373 will be marketed in the European Union as Nuvaxovid COVID-19 Vaccine. “Novavax appreciates the CHMP’s positive opinion concerning our vaccine, and we look forward to a decision from the European Commission,” said Stanley C. Erck, President and Chief Executive Officer, Novavax. “An authorization from the Commission would deliver the first protein-based vaccine to the E.U. during a critical time when we believe having choice among vaccines will lead to increased immunization.”
Novavax and the European Commission announced an advance purchase agreement for up to 200 million doses of Novavax’ COVID-19 vaccine in August 2021. This leverages Novavax’ manufacturing partnership with Serum Institute of India to later supplement with data from additional manufacturing sites in Novavax’ global supply chain.